Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
Copyright © 2022 Elsevier Inc. All rights reserved..
Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p). Fifty-nine patients were included; the median age was 57 years, 55.9% males, 22% ISS-I, 25.4% ISS-II, and 47.5% ISS-III. The majority (89.8%) had one alteration, whereas 10.2% had del(17p) and t(4;14). The frequencies of CA were del(17p) in 61.0%, t(4;14) in 25.4%, and t(14;16) in 3,4%. Autologous stem cell transplantation was performed in 36 cases, 20 patients did not use this consolidative strategy, and this data was missed in three cases. Five-year OS for the entire cohort was 60.8% and 5-year PFS was 28.1%. Bortezomib-based induction regimen (BBR) (p=0.029), consolidation with ASCT (p<0.001), and maintenance therapy (p=0.004) were associated with an improved 5-year OS. In the multivariate analysis, ASCT was the only variable with a positive impact on OS (HR 0.11, 95% CI 0.033 to 0.34, p<0.001). The median PFS presented a non-statistically significant benefit in BBR, ASCT, and maintenance therapy groups. BBR induction, ASCT, and maintenance therapy were associated with improved OS in high-risk NDMM patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Current problems in cancer - 47(2023), 1 vom: 06. Feb., Seite 100916 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garrido, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chromosome aberrations |
|---|
| Anmerkungen: |
Date Completed 17.01.2023 Date Revised 27.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.currproblcancer.2022.100916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349862095 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349862095 | ||
| 003 | DE-627 | ||
| 005 | 20231226043635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.currproblcancer.2022.100916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349862095 | ||
| 035 | |a (NLM)36473780 | ||
| 035 | |a (PII)S0147-0272(22)00075-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garrido, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p). Fifty-nine patients were included; the median age was 57 years, 55.9% males, 22% ISS-I, 25.4% ISS-II, and 47.5% ISS-III. The majority (89.8%) had one alteration, whereas 10.2% had del(17p) and t(4;14). The frequencies of CA were del(17p) in 61.0%, t(4;14) in 25.4%, and t(14;16) in 3,4%. Autologous stem cell transplantation was performed in 36 cases, 20 patients did not use this consolidative strategy, and this data was missed in three cases. Five-year OS for the entire cohort was 60.8% and 5-year PFS was 28.1%. Bortezomib-based induction regimen (BBR) (p=0.029), consolidation with ASCT (p<0.001), and maintenance therapy (p=0.004) were associated with an improved 5-year OS. In the multivariate analysis, ASCT was the only variable with a positive impact on OS (HR 0.11, 95% CI 0.033 to 0.34, p<0.001). The median PFS presented a non-statistically significant benefit in BBR, ASCT, and maintenance therapy groups. BBR induction, ASCT, and maintenance therapy were associated with improved OS in high-risk NDMM patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chromosome aberrations | |
| 650 | 4 | |a Hematopoietic stem cell transplantation | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Slavutsky, Irma |e verfasserin |4 aut | |
| 700 | 1 | |a Riva, Eloisa |e verfasserin |4 aut | |
| 700 | 0 | |a Grupo de Estudio Latinoamericano de Mieloma Múltiple (GELAMM) |e verfasserin |4 aut | |
| 700 | 1 | |a Peña, Camila |e investigator |4 oth | |
| 700 | 1 | |a Schutz, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Tarín-Arzaga, Luz |e investigator |4 oth | |
| 700 | 1 | |a Martínez-Cordero, Humberto |e investigator |4 oth | |
| 700 | 1 | |a Bove, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Osorio, Rocío |e investigator |4 oth | |
| 700 | 1 | |a Chandía, Mauricio |e investigator |4 oth | |
| 700 | 1 | |a Beltrán, Cecilia |e investigator |4 oth | |
| 700 | 1 | |a Schulz, Javier |e investigator |4 oth | |
| 700 | 1 | |a Cardemil, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Contreras, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Vergara, Carmen Gloria |e investigator |4 oth | |
| 700 | 1 | |a Donoso, Javiera |e investigator |4 oth | |
| 700 | 1 | |a Espinoza, Marcela |e investigator |4 oth | |
| 700 | 1 | |a La Rocca, Gabriel |e investigator |4 oth | |
| 700 | 1 | |a López-Vidal, Hernán |e investigator |4 oth | |
| 700 | 1 | |a León, Pilar |e investigator |4 oth | |
| 700 | 1 | |a Hopkins, Christine Rojas |e investigator |4 oth | |
| 700 | 1 | |a Soto, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Aranda, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Torres, Vivianne |e investigator |4 oth | |
| 700 | 1 | |a Roa, Macarena |e investigator |4 oth | |
| 700 | 1 | |a Ochoa, Paola |e investigator |4 oth | |
| 700 | 1 | |a Duarte, Patricio Jose |e investigator |4 oth | |
| 700 | 1 | |a Remaggi, Guillermina |e investigator |4 oth | |
| 700 | 1 | |a Yantorno, Sebastián |e investigator |4 oth | |
| 700 | 1 | |a Corzo, Ariel |e investigator |4 oth | |
| 700 | 1 | |a Zabaljauregui, Soledad |e investigator |4 oth | |
| 700 | 1 | |a Shanley, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Lopresti, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Orlando, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Verri, Verónica |e investigator |4 oth | |
| 700 | 1 | |a Quiroga, Luis |e investigator |4 oth | |
| 700 | 1 | |a García, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Vanesa |e investigator |4 oth | |
| 700 | 1 | |a Ramirez, Jhoanna |e investigator |4 oth | |
| 700 | 1 | |a Verduga, Azucena |e investigator |4 oth | |
| 700 | 1 | |a Molina, Alicia |e investigator |4 oth | |
| 700 | 1 | |a Pacheco, María |e investigator |4 oth | |
| 700 | 1 | |a Mantilla, William |e investigator |4 oth | |
| 700 | 1 | |a Mite, Alex |e investigator |4 oth | |
| 700 | 1 | |a Reyes, Inés |e investigator |4 oth | |
| 700 | 1 | |a Sabando, Brenner |e investigator |4 oth | |
| 700 | 1 | |a Ramírez, Francisca |e investigator |4 oth | |
| 700 | 1 | |a Sossa, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Abello, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Idrobo, Henry |e investigator |4 oth | |
| 700 | 1 | |a Cardenas, Kenny Mauricio Galvez |e investigator |4 oth | |
| 700 | 1 | |a Saavedra, Domingo |e investigator |4 oth | |
| 700 | 1 | |a Quintero, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Gazitúa, Raimundo |e investigator |4 oth | |
| 700 | 1 | |a Gaviria, Lina |e investigator |4 oth | |
| 700 | 1 | |a Gomez, Rigoberto |e investigator |4 oth | |
| 700 | 1 | |a Osuna, Mónica |e investigator |4 oth | |
| 700 | 1 | |a Henao-Uribe, Alicia |e investigator |4 oth | |
| 700 | 1 | |a Cantú-Martínez, Omar |e investigator |4 oth | |
| 700 | 1 | |a Gómez-Almaguer, David |e investigator |4 oth | |
| 700 | 1 | |a García-Navarrete, Yarely Itzayana |e investigator |4 oth | |
| 700 | 1 | |a Cruz-Mora, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Cantero-Fortiz, Yahveth |e investigator |4 oth | |
| 700 | 1 | |a Ruiz-Argüelles, Guillermo J |e investigator |4 oth | |
| 700 | 1 | |a Fantl, Dorotea |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current problems in cancer |d 1993 |g 47(2023), 1 vom: 06. Feb., Seite 100916 |w (DE-627)NLM000438111 |x 1535-6345 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g number:1 |g day:06 |g month:02 |g pages:100916 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.currproblcancer.2022.100916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |e 1 |b 06 |c 02 |h 100916 | ||